Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAEP NASDAQ:DMAA NYSE:DNI NYSE:HYAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAEPCantor Equity Partners III$10.37-0.8%$0.00$10.30▼$11.09$317.12MN/A205,335 shs6,869 shsDMAADrugs Made In America Acquisition$10.25+0.2%$0.00$9.95▼$10.28$298.99MN/A102,865 shs7,701 shsDNIDividend and Income Fund$9.79$9.76$6.55▼$13.97$121.89M1.3363,824 shs88,009 shsHYACHaymaker Acquisition Corp. 4$11.19-0.1%$0.00$10.59▼$11.20$330.66M-0.02105,256 shs86,401 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAEPCantor Equity Partners III-0.29%-0.85%-1.14%+1,044,999,900.00%+1,044,999,900.00%DMAADrugs Made In America Acquisition-0.49%-0.29%+1,022,999,900.00%+1,022,999,900.00%+1,022,999,900.00%DNIDividend and Income Fund0.00%0.00%0.00%0.00%0.00%HYACHaymaker Acquisition Corp. 40.00%0.00%+1,119,999,900.00%+1,119,999,900.00%+1,119,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAEPCantor Equity Partners IIIN/AN/AN/AN/AN/AN/AN/AN/ADMAADrugs Made In America AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ADNIDividend and Income FundN/AN/AN/AN/AN/AN/AN/AN/AHYACHaymaker Acquisition Corp. 4N/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAEPCantor Equity Partners III 0.00N/AN/AN/ADMAADrugs Made In America Acquisition 0.00N/AN/AN/ADNIDividend and Income Fund 0.00N/AN/AN/AHYACHaymaker Acquisition Corp. 4 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAEPCantor Equity Partners IIIN/AN/AN/AN/AN/AN/ADMAADrugs Made In America AcquisitionN/AN/AN/AN/AN/AN/ADNIDividend and Income FundN/AN/AN/AN/AN/AN/AHYACHaymaker Acquisition Corp. 4N/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAEPCantor Equity Partners IIIN/AN/A0.00∞N/AN/AN/AN/AN/ADMAADrugs Made In America AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ADNIDividend and Income FundN/AN/A0.00∞N/AN/AN/AN/AN/AHYACHaymaker Acquisition Corp. 4N/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAEPCantor Equity Partners IIIN/AN/AN/AN/AN/ADMAADrugs Made In America AcquisitionN/AN/AN/AN/AN/ADNIDividend and Income Fund$0.959.70%N/AN/AN/AHYACHaymaker Acquisition Corp. 4N/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAEPCantor Equity Partners IIIN/ADMAADrugs Made In America AcquisitionN/ADNIDividend and Income Fund42.47%HYACHaymaker Acquisition Corp. 471.07%Insider OwnershipCompanyInsider OwnershipCAEPCantor Equity Partners IIIN/ADMAADrugs Made In America AcquisitionN/ADNIDividend and Income Fund1.00%HYACHaymaker Acquisition Corp. 422.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAEPCantor Equity Partners III230.58 millionN/AN/ADMAADrugs Made In America Acquisition229.17 millionN/AN/ADNIDividend and Income FundN/A12.45 millionN/ANot OptionableHYACHaymaker Acquisition Corp. 4N/A29.55 million23.00 millionN/ADNI, HYAC, CAEP, and DMAA HeadlinesRecent News About These CompaniesMizuho Securities USA LLC Increases Stock Holdings in Haymaker Acquisition Corp. 4 (NYSE:HYAC)August 12 at 8:26 AM | marketbeat.comHaymaker Acquisition Corp. 4 (NYSE:HYAC) Stock Rating Upgraded by Wall Street ZenAugust 5, 2025 | americanbankingnews.comHaymaker Acquisition Corp. 4 (NYSE:HYAC) Upgraded to Hold at Wall Street ZenAugust 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNI, HYAC, CAEP, and DMAA Company DescriptionsCantor Equity Partners III NASDAQ:CAEP$10.37 -0.08 (-0.77%) As of 01:31 PM EasternWe are a blank check company incorporated on November 11, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any discussions, directly or indirectly, with any business combination target regarding an initial business combination with our company. Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although we expect to focus on a target in an industry where we believe our management team’s and our affiliates’ expertise will provide us with a competitive advantage, including the financial services, digital assets, healthcare, real estate services, technology and software industries. Further, our efforts to identify a prospective target business will not be limited to any characteristics, although we expect to favor potential target companies with certain characteristics which include, but are not limited to, positive long term growth prospects, competitive advantages, consolidation opportunities, recurring revenue or the potential for recurring revenue, opportunities for operational improvement and attractive margins or the potential for attractive margins. Our executive offices are located New York, New York.Drugs Made In America Acquisition NASDAQ:DMAA$10.25 +0.02 (+0.20%) As of 11:59 AM EasternDrugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.Dividend and Income Fund NYSE:DNIHaymaker Acquisition Corp. 4 NYSE:HYAC$11.19 -0.01 (-0.09%) As of 09:42 AM EasternHaymaker Acquisition Corp. 4 is a blank check company. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. Haymaker Acquisition Corp. 4 is based in New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Pulls Back Into a Screaming Buy Intel's White House Reset: From Political Storm to a Clearer Sky AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces If Qualcomm Holds $145, Its Next Move Could Be Massive Alphabet Reclaims $200 Threshold—Bull Run Reignited? NFL and WWE Land on ESPN—The Impact on Disney and TKO Stocks Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.